We are live on ! Find out more
WM

WS Management Portfolio holdings

AUM $1.14B Turnover 33.87%
1-Year Est. Return 139.27%
This Fund
S&P 500
This Quarter Est. Return
+11.14%
1 Year Est. Return
+139.27%
3 Year Est. Return
+309.04%
5 Year Est. Return
+400.83%
10 Year Est. Return
+1,509.99%
AUM
$927M
AUM Growth
+$112M
Cap. Flow
+$51.2M
Cap. Flow %
5.53%
Top 10 Hldgs %
64.53%
Holding
66
New
11
Increased
10
Reduced
10
Closed
3
Avg Time Held Equity + Options
3 years
Top 10 Avg Time Held Equity + Options
1.7 years
Top 20 Avg Time Held Equity + Options
1.7 years
Avg Time Held Equity only
3.7 years
Top 10 Avg Time Held Equity only
1.7 years
Top 20 Avg Time Held Equity only
2.3 years

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$44.9M
2
TWTR
Twitter, Inc.
TWTR
+$12.7M
3
FCX icon
Freeport-McMoran
FCX
+$9.38M
4
KNX icon
Knight Transportation
KNX
+$6.86M
5
KMX icon
CarMax
KMX
+$6.49M

Sector Composition

Rank Sector Weight
1 Financials 29.31%
2 Miscellaneous 29.25%
3 Communication Services 10.95%
4 Technology 7.87%
5 Consumer Discretionary 6.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SLB icon
51
SLB Ltd
SLB
$71.8B
$1.42M 0.15%
91,300
– –
2013 Q2
29 quarters
RARE icon
52
Ultragenyx Pharmaceutical
RARE
$1.5B
$1.37M 0.15%
16,692
– –
2018 Q2
9 quarters
CLLS icon
53
Cellectis
CLLS
$111M
$990K 0.11%
53,506
– –
2018 Q2
9 quarters
ADAP
54
DELISTED
Adaptimmune Therapeutics
ADAP
$970K 0.1%
121,543
– –
2018 Q2
9 quarters
VTLE icon
55
DELISTED
Vital Energy
VTLE
$855K 0.09%
87,205
– –
2015 Q2
21 quarters
EDIT icon
56
Editas Medicine
EDIT
$375M
$849K 0.09%
30,263
– –
2018 Q2
9 quarters
NTLA icon
57
Intellia Therapeutics
NTLA
$1.59B
$835K 0.09%
42,018
– –
2018 Q2
9 quarters
SGMO icon
58
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$801K 0.09%
84,811
– –
2018 Q2
9 quarters
UBER icon
59
CALL
Uber
UBER
$146B
$730K 0.08%
+20,000
New +$660K
2020 Q3
0 quarters
BLUE icon
60
DELISTED
bluebird bio
BLUE
$636K 0.07%
910
– –
2018 Q2
9 quarters
AUD
61
DELISTED
Audacy, Inc.
AUD
$531K 0.06%
329,694
– –
2017 Q3
12 quarters
WVE icon
62
Wave Life Sciences
WVE
$629M
$380K 0.04%
44,816
– –
2018 Q2
9 quarters
ABEO icon
63
Abeona Therapeutics
ABEO
$266M
$99K 0.01%
3,887
– –
2018 Q2
9 quarters
CVNA icon
64
PUT
Carvana
CVNA
$66.7B
– –
-383,000
Closed -$9.21M –
MU icon
65
PUT
Micron Technology
MU
$1.05T
– –
-234,300
Closed -$12.1M –
QQQ icon
66
PUT
Invesco QQQ Trust
QQQ
$487B
– –
-171,900
Closed -$42.6M –

Similar funds

WS Management's Q3 2020 Portfolio in Review

As of Q3 2020, WS Management held 66 positions worth $927M, up 14% from $816M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

WS Management deployed $51.2M of net new capital in Q3 2020, opening 11 new positions and adding to 10 existing holdings. Its largest new stake was Freeport-McMoran: 650,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Financials at 29% of assets, down from 31% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Berkshire Hathaway Class B, an estimated $31.1M trimmed.

  • WS Management's largest Q3 2020 buy was Freeport-McMoran: 650,000 shares worth $10.2M.
  • WS Management added most to SPDR Gold Trust in Q3 2020, an estimated $44.9M increase.
  • WS Management's biggest Q3 2020 reduction was Berkshire Hathaway Class B, cutting an estimated $31.1M.
  • WS Management's ten largest holdings make up 65% of its $927M portfolio in Q3 2020.
  • WS Management opened 11 new positions and closed 3 in Q3 2020.
  • WS Management's portfolio value rose 14% quarter-over-quarter to $927M.

Based on WS Management's 13F filing for Q3 2020, filed 12 Nov 2020.